{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:30:21Z","timestamp":1790836221600,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"am","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005737","name":"Universit\u00e9 Pierre et Marie Curie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ejca.2020.04.040","type":"journal-article","created":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T11:12:54Z","timestamp":1593342774000},"page":"221-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Chemoradiotherapy efficacy is predicted by intra-tumour CD8+\/FoxP3+ double positive T cell density in locally advanced N2 non\u2013small-cell lung carcinoma"],"prefix":"10.1016","volume":"135","author":[{"given":"G.","family":"Boulle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Velut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mansuet-Lupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Blons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Fournel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Cremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wislez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Duchatelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tr\u00e9daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Alifano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Damotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.04.040_bib1","first-page":"123","article-title":"Role of adjuvant radiotherapy in completely resected non-small-cell lung cancer","volume":"11","author":"P\u00e9choux","year":"2013","journal-title":"EJC Suppl EJC Off J EORTC Eur Organ Res Treat Cancer Al"},{"key":"10.1016\/j.ejca.2020.04.040_bib2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of Four Chemotherapy Regimens for Advanced Non\u2013Small-Cell Lung Cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.04.040_bib3","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.2000.18.16.2981","article-title":"Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications","volume":"18","author":"Andre","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.040_bib4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.radonc.2012.12.003","article-title":"The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05)","volume":"106","author":"Ball","year":"2013","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ejca.2020.04.040_bib5","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.04.040_bib6","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.04.040_bib7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1158\/0008-5472.CAN-13-1342","article-title":"Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells","volume":"74","author":"Goc","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2020.04.040_bib8","doi-asserted-by":"crossref","first-page":"e1255394","DOI":"10.1080\/2162402X.2016.1255394","article-title":"Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients","volume":"5","author":"Remark","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejca.2020.04.040_bib9","doi-asserted-by":"crossref","first-page":"e0153954","DOI":"10.1371\/journal.pone.0153954","article-title":"PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC","volume":"11","author":"Ameratunga","year":"2016","journal-title":"PloS One"},{"issue":"55","key":"10.1016\/j.ejca.2020.04.040_bib10","first-page":"7","article-title":"Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy","volume":"2016","author":"Tokito","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.ejca.2020.04.040_bib11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/cam4.1243","article-title":"Prognostic value of PD-L1 expression in combination with CD8+ TILs density in patients with surgically resected non-small cell lung cancer","volume":"7","author":"Yang","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2020.04.040_bib12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2015.05.007","article-title":"PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma","volume":"89","author":"Cooper","year":"2015","journal-title":"Lung Cancer Amst Neth"},{"key":"10.1016\/j.ejca.2020.04.040_bib13","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1158\/1078-0432.CCR-08-0133","article-title":"Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer","volume":"14","author":"Al-Shibli","year":"2008","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2020.04.040_bib14","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1002\/cncr.22282","article-title":"Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients","volume":"107","author":"Petersen","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2020.04.040_bib15","doi-asserted-by":"crossref","first-page":"36065","DOI":"10.18632\/oncotarget.9130","article-title":"Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: a systematic review with meta-analysis","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"issue":"Suppl","key":"10.1016\/j.ejca.2020.04.040_bib16","article-title":"Radiotherapy for primary lung carcinoma","volume":"20","author":"Giraud","year":"2016","journal-title":"Cancer Radiother J Soc Francaise Radiother Oncol"},{"key":"10.1016\/j.ejca.2020.04.040_bib17","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2020.04.040_bib18","doi-asserted-by":"crossref","first-page":"13765","DOI":"10.18632\/oncotarget.7282","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer","volume":"7","author":"Zeng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2020.04.040_bib19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/ijc.25693","article-title":"CD8+Foxp3+ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response","volume":"129","author":"Le","year":"2011","journal-title":"Int J Cancer J Int Cancer"},{"key":"10.1016\/j.ejca.2020.04.040_bib20","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/gut.2008.158824","article-title":"Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue","volume":"58","author":"Chaput","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.ejca.2020.04.040_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00171","article-title":"Human and Mouse CD8+CD25+FOXP3+ Regulatory T Cells at Steady State and during Interleukin-2 Therapy","volume":"6","author":"Churlaud","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2020.04.040_bib22","article-title":"Analysis of immune microenvironment by multiplex immunohistochemistry in locally advanced non-small cell lung cancer: Principles and perspectives","author":"Boulle","year":"2018","journal-title":"Cancer Radiother J Soc Francaise Radiother Oncol"},{"key":"10.1016\/j.ejca.2020.04.040_bib23","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jtho.2016.10.015","article-title":"Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases","volume":"12","author":"Uruga","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2020.04.040_bib24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/annonc\/mdy014","article-title":"Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer","volume":"29","author":"Adam","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2020.04.040_bib25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ejca.2020.04.040_bib26","unstructured":"Radiation therapy in treating patients with non small cell lung cancer that has been completely removed by surgery - Full text view - ClinicalTrials.gov. n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00410683 (accessed February 11, 2018)."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:28:47Z","timestamp":1760732927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920302458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":26,"alternative-id":["S0959804920302458"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.04.040","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemoradiotherapy efficacy is predicted by intra-tumour CD8+\/FoxP3+ double positive T cell density in locally advanced N2 non\u2013small-cell lung carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.04.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}